Vogligold M 0.2. Uses, Dosage, and Side Effects - Steris Healthcare PVT LTD.....

Vogligold M 0.2

Voglibose 0.2 mg + Metformin SR 500

Vogligold M 0.2 is a combination oral antidiabetic medication designed to Voglibose 0.2 mg + Metformin SR 500 enhance glycemic control in adults with Type 2 diabetes mellitus. This formulation combines Voglibose, an alpha-glucosidase inhibitor, with Metformin, a biguanide. Together, these two agents provide a comprehensive approach to managing blood glucose levels, particularly effective for patients who struggle with postprandial hyperglycemia.

Composition

• Active Ingredients:
  • Voglibose (0.2mg)
  • Metformin Hydrochloride (500mg or 850mg, depending on the specific product variation)
• Excipients: Microcrystalline cellulose, lactose monohydrate, magnesium stearate, hypromellose, and other inactive ingredients that ensure the stability and efficacy of the tablet.

Mechanism of Action

Vogligold M 0.2 works through the combined mechanisms of its two active ingredients:

• Voglibose: Inhibits the enzyme alpha-glucosidase in the small intestine. This enzyme is responsible for breaking down complex carbohydrates into simple sugars, which are then absorbed into the bloodstream. By inhibiting alpha-glucosidase, Voglibose slows down the digestion and absorption of carbohydrates, resulting in a gradual rise in blood glucose levels after meals. This helps prevent postprandial hyperglycemia.
• Metformin: Decreases hepatic glucose production, reduces intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. This results in lower blood glucose levels, both fasting and postprandial.

Indications

Vogligold M 0.2 is indicated for:

• Type 2 Diabetes Mellitus: Used to improve glycemic control in adults with Type 2 diabetes, especially when diet, exercise, and other antidiabetic medications do not provide adequate control.
• Postprandial Hyperglycemia: Particularly effective in managing high blood sugar levels that occur after meals.

Dosage and Administration

• Standard Dosage: The typical starting dose is one tablet taken twice or thrice daily with meals to reduce gastrointestinal side effects. The dosage may be adjusted based on the patient’s needs and the prescribing physician’s advice.
• Administration: Vogligold M 0.2 should be taken with food to minimize gastrointestinal discomfort. Tablets should be swallowed whole with water.
• Dose Adjustments: Adjustments may be necessary based on the patient's response to treatment and renal function. Regular monitoring of blood glucose levels is essential to ensure optimal dosing.

Benefits

• Effective Glycemic Control: The combination of Voglibose and Metformin offers superior glycemic control compared to monotherapy.
• Reduced Postprandial Hyperglycemia: Helps manage and reduce post-meal blood sugar spikes, improving overall glycemic control.
• Weight Neutral or Weight Loss: Metformin is often associated with weight loss or at least weight neutrality, which is beneficial for overweight or obese patients with Type 2 diabetes.
• Reduced Risk of Hypoglycemia: Voglibose has a lower risk of causing hypoglycemia compared to some other antidiabetic medications.

Side Effects

While Vogligold M 0.2 is generally well-tolerated, it may cause some side effects, including:

• Gastrointestinal Issues: Flatulence, diarrhea, and abdominal discomfort are common, particularly during the initial phase of treatment. These symptoms usually diminish over time as the body adjusts to the medication.
• Hypoglycemia: Although rare, hypoglycemia can occur, especially if Vogligold M 0.2 is used in combination with other antidiabetic medications.
• Elevated Liver Enzymes: Regular monitoring of liver function tests is recommended as Voglibose can cause transient elevations in liver enzymes.
• Lactic Acidosis: A rare but serious complication of Metformin. Symptoms include muscle pain, difficulty breathing, stomach pain, dizziness, and fatigue. Immediate medical attention is required if these symptoms develop.

Precautions and Warnings

• Regular Monitoring: Patients should have their blood glucose levels regularly monitored to ensure the medication is effectively managing their diabetes.
• Renal Function: Patients with renal impairment should have their kidney function regularly monitored, and dose adjustments may be necessary.
• Liver Function Tests: Liver enzymes should be checked before starting treatment and periodically thereafter, as both active ingredients can cause liver enzyme elevations.
• Contraindications: Not recommended for patients with a history of hypersensitivity to Voglibose, Metformin, or any of their components. Also contraindicated in patients with severe renal impairment, metabolic acidosis, or a history of lactic acidosis.
• Pregnancy and Nursing: The safety of Voglibose and Metformin during pregnancy and breastfeeding has not been established. It should only be used if the potential benefits justify the potential risks.

Drug Interactions

• Other Antidiabetic Agents: When used in combination with other antidiabetic medications, there may be an increased risk of hypoglycemia.
• Digestive Enzyme Supplements: These may reduce the efficacy of Voglibose by enhancing the breakdown of carbohydrates.
• Corticosteroids: May reduce the blood glucose-lowering effect of Voglibose and Metformin.
• Diuretics: Can increase the risk of lactic acidosis when taken with Metformin.

Conclusion

Vogligold M 0.2, combining Voglibose and Metformin, provides a comprehensive and effective approach to managing Type 2 diabetes mellitus. Its dual mechanism of action helps to regulate blood glucose levels, improve glycemic control, and reduce the risk of postprandial hyperglycemia. With benefits such as improved glycemic control, reduced post-meal blood sugar spikes, convenient dosing, and a lower risk of hypoglycemia, Vogligold M 0.2 is a valuable addition to diabetes management. Regular monitoring and adherence to prescribed guidelines are crucial for maximizing the therapeutic benefits and minimizing potential side effects. Vogligold M 0.2 remains an important option in the treatment of Type 2 diabetes, helping patients achieve better health outcomes and improved quality of life.Steris Healthcare Pvt Ltd, founded by a group of expert professionals in the pharmaceutical industry in February 2018, operates as Sterispharma. This company, which is based in Navi Mumbai, holds certifications from WHO, GMP, and ISO. Its commitment is to provide high-quality drugs at affordable prices to its customers throughout India, following the rigorous guidelines set by the WHO. Steris offers the convenience of an online pharmacy where customers can easily buy medicines and enjoy the benefit of home delivery. At Steris, the mission is to supply a wide array of healthcare products designed to meet the varied needs of the medical community. Whether it is advanced treatments, medications for rare conditions, or basic health necessities, Sterispharma strives to serve the healthcare industry’s broad demands. The extensive product lineup from Steris includes treatments for various health areas such as Cardiology, Asthma, Respiratory issues, Nasal conditions, Diabetes, Endocrinology, Gastroenterology, Orthopedics, Anti-infectives/antibiotics, General Medicine, Urology, Neurology, Nephrology, Oncology, Gynecology, Pediatrics, Dental care, and Dermatology.

For further information: 

EMAIL:  info@sterispharma.com  / contact@sterispharma.com   

CALL/WHATSAPP: 7877551268, 7849827488

BUY NOW